The proluton study aimed to identify the molecular mediators of beneficiary survival effect of a single depot hydroxyl-progesterone dose in node positive patients eligible for upfront surgical resection (PMID: 21670457). We subjected patient samples before, and after, hydroxyl-progesterone peri-operative intervention, to whole transcriptome sequencing on a next generation sequencing platform.